▲From left, HyeJeoung Lee, Director at JNPMEDI, and HanYeong Oh, PL at JNPMEDI (Photo courtesy of JNPMEDI)
As digital healthcare technology has become a core driver in the global medical industry, its regulatory approval standards are rapidly evolving. The U.S. FDA and the European Union (EU), in particular, are introducing advanced regulatory frameworks for new types of digital products, such as Software as a Medical Device (SaMD) and AI-powered diagnostic products. This is significantly impacting the overseas expansion strategies of Korean medical device companies, hospitals, and digital health tech firms.
From Technology-Centric to Regulation-Centric: A Paradigm Shift Begins
Traditional medical device approvals relied on verification systems centered on physical safety and clinical performance. However, digital medical products inherently demand a data-centric evaluation system, especially since AI algorithms are not static; their outcomes can continuously change through learning.
Consequently, regulatory bodies are now focusing less on "what" was made and more on "how" it was made and "how" it will be managed. Technology alone can no longer explain a product; the reliability of data, transparency of algorithms, and the design of cybersecurity systems are all comprehensively scrutinized.
U.S. FDA Strengthens Life-Cycle Based SaMD Evaluation System
The U.S. FDA is enhancing its life-cycle based review system to account for the dynamic nature of digital healthcare products. For AI/ML-based software, continuous learning and version updates are essential even after commercialization. The Pre-determined Change Control Plan (PCCP) system directly addresses this by incorporating future updates into pre-market review.
PCCP allows for expedited approval of subsequent updates based on the algorithm modification plan and scope submitted by the developer during initial product approval, providing both regulatory predictability and flexibility. To leverage this, companies must submit plans covering ▲data set diversity ▲performance validation ▲version management ▲verifiable change control strategies from the early stages.
Europe's CE MDR Toughens SaMD Regulations: GDPR Compliance is a Must
The European Union (EU) has also significantly tightened regulatory standards for digital medical devices through the CE MDR. Notably, Rule 11 classifies software with diagnostic support, treatment decision, or health status assessment functions as medical devices, meaning even simple wearable apps or monitoring tools now require certification.
Furthermore, compliance with GDPR (General Data Protection Regulation) is mandatory in the European market. If sensitive data like patient biometric information, diagnostic images, or health records are stored on cloud-based platforms or processed remotely, a Privacy Impact Assessment and a security design report are required in addition to CE certification.
One Korean company experienced a delay of several months in its European certification process for an AI-based cardiovascular risk prediction software due to insufficient GDPR compliance. They only obtained CE certification after strengthening their security design with external legal consultation.
From Design to Approval: "Regulations Now Begin at the Planning Stage"
As the global regulatory environment becomes more complex, it is crucial to manage product development and regulatory strategy as an integrated process, not parallel ones. For data-driven algorithm products like SaMD or digital therapeutics, failing to consider approval requirements and technical documentation from the initial design phase can lead to significant risks later on.
In this landscape, domestic digital healthcare companies urgently need collaboration across various specialized fields, including ▲global regulatory strategy formulation ▲clinical trial design and operation ▲technical documentation ▲security/privacy design. Since it is challenging to address all these within a single organization, partnering with experienced regulatory and clinical experts is becoming a key factor.
'Regulatory Compliance Capability' is Key to Global Success: JNPMEDI's Strategic Support for Global Expansion of SaMD & AI Medical Devices
The digital healthcare market is projected to grow at an average annual rate of over 20% for the next five years, with demand for SaMD and AI-based solutions expected to accelerate even further. However, technology alone is not enough for success. This market demands comprehensive capabilities, including regulatory strategy formulation, technical documentation completeness, data reliability, and robust security system design.
An industry official stated, "The more innovative the technology, the more strategic the regulatory response must be. Collaboration with a partner that encompasses the entire process—from planning and development to clinical trials and approval—is essential for global competitiveness."
Indeed, digital healthcare is moving beyond an era of pure technology into an era of regulatory design. To transform product potential into reality, collaboration with a fitting regulatory compliance partner has become more vital than ever. In response, JNPMEDI provides expert consulting and clinical operation services for the global regulatory approval of digital medical devices.
Specifically, the company offers integrated services for projects targeting the U.S. FDA and European CE MDR, including: ▲FDA and CE MDR strategy consulting ▲SaMD and AI medical device technical documentation ▲clinical trial design and operation (ISO 14155 based) ▲GDPR and cybersecurity document consultation ▲pre-submission and notified body engagement.
Furthermore, JNPMEDI recently established a dedicated Digital Healthcare Task Force in collaboration with multinational CROs and security experts. This TF is actively pursuing U.S. FDA IDE clinical approvals for domestic manufacturers, CE MDR review responses in Europe, and pre-PCCP strategic planning.
📌 Reference: Invest News (Link)
▲From left, HyeJeoung Lee, Director at JNPMEDI, and HanYeong Oh, PL at JNPMEDI (Photo courtesy of JNPMEDI)
As digital healthcare technology has become a core driver in the global medical industry, its regulatory approval standards are rapidly evolving. The U.S. FDA and the European Union (EU), in particular, are introducing advanced regulatory frameworks for new types of digital products, such as Software as a Medical Device (SaMD) and AI-powered diagnostic products. This is significantly impacting the overseas expansion strategies of Korean medical device companies, hospitals, and digital health tech firms.
From Technology-Centric to Regulation-Centric: A Paradigm Shift Begins
Traditional medical device approvals relied on verification systems centered on physical safety and clinical performance. However, digital medical products inherently demand a data-centric evaluation system, especially since AI algorithms are not static; their outcomes can continuously change through learning.
Consequently, regulatory bodies are now focusing less on "what" was made and more on "how" it was made and "how" it will be managed. Technology alone can no longer explain a product; the reliability of data, transparency of algorithms, and the design of cybersecurity systems are all comprehensively scrutinized.
U.S. FDA Strengthens Life-Cycle Based SaMD Evaluation System
The U.S. FDA is enhancing its life-cycle based review system to account for the dynamic nature of digital healthcare products. For AI/ML-based software, continuous learning and version updates are essential even after commercialization. The Pre-determined Change Control Plan (PCCP) system directly addresses this by incorporating future updates into pre-market review.
PCCP allows for expedited approval of subsequent updates based on the algorithm modification plan and scope submitted by the developer during initial product approval, providing both regulatory predictability and flexibility. To leverage this, companies must submit plans covering ▲data set diversity ▲performance validation ▲version management ▲verifiable change control strategies from the early stages.
Europe's CE MDR Toughens SaMD Regulations: GDPR Compliance is a Must
The European Union (EU) has also significantly tightened regulatory standards for digital medical devices through the CE MDR. Notably, Rule 11 classifies software with diagnostic support, treatment decision, or health status assessment functions as medical devices, meaning even simple wearable apps or monitoring tools now require certification.
Furthermore, compliance with GDPR (General Data Protection Regulation) is mandatory in the European market. If sensitive data like patient biometric information, diagnostic images, or health records are stored on cloud-based platforms or processed remotely, a Privacy Impact Assessment and a security design report are required in addition to CE certification.
One Korean company experienced a delay of several months in its European certification process for an AI-based cardiovascular risk prediction software due to insufficient GDPR compliance. They only obtained CE certification after strengthening their security design with external legal consultation.
From Design to Approval: "Regulations Now Begin at the Planning Stage"
As the global regulatory environment becomes more complex, it is crucial to manage product development and regulatory strategy as an integrated process, not parallel ones. For data-driven algorithm products like SaMD or digital therapeutics, failing to consider approval requirements and technical documentation from the initial design phase can lead to significant risks later on.
In this landscape, domestic digital healthcare companies urgently need collaboration across various specialized fields, including ▲global regulatory strategy formulation ▲clinical trial design and operation ▲technical documentation ▲security/privacy design. Since it is challenging to address all these within a single organization, partnering with experienced regulatory and clinical experts is becoming a key factor.
'Regulatory Compliance Capability' is Key to Global Success: JNPMEDI's Strategic Support for Global Expansion of SaMD & AI Medical Devices
The digital healthcare market is projected to grow at an average annual rate of over 20% for the next five years, with demand for SaMD and AI-based solutions expected to accelerate even further. However, technology alone is not enough for success. This market demands comprehensive capabilities, including regulatory strategy formulation, technical documentation completeness, data reliability, and robust security system design.
An industry official stated, "The more innovative the technology, the more strategic the regulatory response must be. Collaboration with a partner that encompasses the entire process—from planning and development to clinical trials and approval—is essential for global competitiveness."
Indeed, digital healthcare is moving beyond an era of pure technology into an era of regulatory design. To transform product potential into reality, collaboration with a fitting regulatory compliance partner has become more vital than ever. In response, JNPMEDI provides expert consulting and clinical operation services for the global regulatory approval of digital medical devices.
Specifically, the company offers integrated services for projects targeting the U.S. FDA and European CE MDR, including: ▲FDA and CE MDR strategy consulting ▲SaMD and AI medical device technical documentation ▲clinical trial design and operation (ISO 14155 based) ▲GDPR and cybersecurity document consultation ▲pre-submission and notified body engagement.
Furthermore, JNPMEDI recently established a dedicated Digital Healthcare Task Force in collaboration with multinational CROs and security experts. This TF is actively pursuing U.S. FDA IDE clinical approvals for domestic manufacturers, CE MDR review responses in Europe, and pre-PCCP strategic planning.
📌 Reference: Invest News (Link)